teaser
zika
clinic
outcom
might
nefari
impact
newborn
lifetim
still
drug
avail
cure
zika
provid
guidanc
help
understand
advanc
search
cure
zika
viru
zikv
remain
global
health
concern
origin
discov
africa
zikv
becam
epidem
year
later
reach
sever
tropic
region
america
africa
asia
despit
caus
mild
symptom
fever
rash
conjunct
major
concern
zikv
regard
sever
neurolog
disord
microcephali
craniofaci
disproport
spastic
seizur
irrit
brainstem
dysfunct
infant
head
comput
tomograph
find
subject
infect
pregnanc
confirm
causal
relationship
microcephali
zika
infect
recent
studi
yuan
cowork
demonstr
singl
mutat
premembran
prm
structur
protein
increas
zikv
infect
neural
progenitor
cell
npc
make
viru
virul
mutat
aros
french
polynesia
strain
contribut
increas
incid
microcephali
higher
mortal
neonat
accord
experiment
assay
disord
attribut
zika
infect
mainli
affect
infant
also
impact
adult
zikvrel
case
syndrom
myeliti
uveiti
meningoenceph
report
adult
current
neither
specif
antivir
drug
vaccin
avail
treat
prevent
zikv
infect
howev
sever
promis
drug
target
encod
viru
present
host
cell
sever
report
compound
found
activ
zikv
protein
present
comprehens
az
review
recent
advanc
zikv
drug
design
includ
viral
host
cell
inhibitor
sever
experiment
comput
techniqu
appli
studi
inform
contribut
design
drug
zikv
relat
virus
zikv
spheric
envelop
viru
icosahedrallik
symmetri
fig
belong
genu
flaviviru
scheme
zika
viru
zikv
surfac
structur
nonstructur
protein
surfaceshad
depth
cu
represent
matur
zikv
built
use
ucsf
chimera
packag
http
wwwrbviucsfeduchimera
base
pdb
id
show
icosahedrallik
symmetri
arrang
surfac
protein
b
virion
compon
highlight
e
c
protein
well
genom
rna
zikv
encod
larg
polyprotein
process
yield
three
structur
protein
c
e
seven
nonstructur
protein
proteas
helicas
domain
methyltransferas
rna
polymeras
domain
built
use
vmd
program
http
wwwksuiuceduresearchvmd
domain
repres
separ
two
distinct
target
methyltransferas
attach
polymeras
domain
form
fulllength
c
zikv
infecti
life
cycl
viru
attach
subsequ
intern
receptormedi
endocytosi
viru
traffick
earli
endosom
acid
environ
induc
fusion
viru
host
membran
result
particl
disassembl
genom
releas
rna
replic
translat
singl
polyprotein
process
host
virusencod
protein
follow
translat
replic
complex
assembl
associ
virusinduc
membran
viral
replic
take
place
progeni
rna
strand
either
initi
new
translat
cycl
assembl
virion
within
endoplasm
reticulum
er
result
immatur
virion
transport
transgolgi
immatur
virion
transform
matur
infecti
particl
releas
exocytosi
pink
box
name
compound
inhibit
mark
step
viru
lifecycl
flavivirida
famili
zikv
carri
positivesens
singlestrand
rna
genom
encod
larg
polyprotein
process
host
viral
proteas
yield
three
structur
seven
nonstructur
ns
protein
fig
envelop
protein
e
membran
protein
express
prm
precursor
capsid
c
structur
protein
form
virion
ns
protein
essenti
genom
replic
modul
host
immun
fig
figur
present
overview
replic
process
zikv
infect
cell
show
mark
step
replic
inhibit
compound
discuss
review
also
present
special
section
see
supplementari
materi
onlin
viral
entri
replic
mechan
initi
avail
zikv
structur
earli
march
sever
effort
develop
homolog
model
zikv
protein
base
close
homolog
dengu
viru
denv
see
glossari
flavivirus
sinc
late
march
zikv
protein
structur
determin
mostli
xray
crystallographi
made
avail
databas
protein
data
bank
pdb
proteas
helicas
methyltransferas
polymeras
fullprotein
envelop
glycoprotein
tabl
among
proteas
helicas
methyltransferas
structur
avail
ligand
atp
rna
use
ligandbindingsit
identif
virtual
screen
versu
apo
conform
protein
structur
fundament
perform
experiment
comput
studi
figur
show
zikv
protein
structur
ligand
substrat
bind
pocket
substrat
bind
pocket
zikv
proteas
residu
residu
fig
base
cocrystal
compound
boron
inhibitor
bind
similar
pocket
helicas
present
two
bind
site
one
encompass
rna
strand
atp
molecul
bind
fig
fulllength
protein
contain
two
domain
repres
distinct
target
methyltransferas
polymeras
polymeras
domain
three
adjac
bind
site
activ
site
rna
site
ntp
channel
fig
methyltransferas
domain
two
substrat
sam
cosubstr
involv
methyl
group
transfer
gtp
substrat
rna
synthesi
consequ
access
two
substrat
togeth
conserv
catalyt
tetrad
form
activ
site
fig
zikv
envelop
protein
compos
three
distinct
domain
bbarrelshap
domain
di
fingerlik
domain
dii
immunoglobulinlik
domain
diii
fig
domain
ii
respons
dimer
bind
site
di
diii
enclos
hydrophob
caviti
around
flexibl
linker
comput
predict
proteinprotein
bind
pocket
compos
residu
di
diii
fig
crystallograph
structur
capsid
protein
recent
solv
contain
four
helic
monom
form
dimer
fig
predict
capsid
pocket
druggabl
use
pockdrug
server
identifi
three
pocket
pocket
helic
pocket
ntermin
helix
monom
pocket
helic
monom
viral
protein
play
import
part
viru
infect
replic
process
e
glycoprotein
associ
viru
adsorpt
intern
fusion
host
cell
well
develop
neutral
humor
immun
prm
protein
sever
role
flaviviru
lifecycl
assist
chaperonemedi
fold
e
protein
prevent
prematur
fusion
virion
egress
main
role
c
protein
assembl
packag
viral
rna
genom
form
viral
nucleocapsid
addit
act
element
viral
particl
assembl
associ
protein
lipid
droplet
endoplasm
reticulum
er
function
ns
flaviviru
protein
still
complet
understood
summar
follow
sever
role
includ
flavivir
replic
virion
matur
subdomain
requir
proper
format
substrat
recognit
site
proteas
helicas
protein
promot
separ
rna
strand
viral
replic
unwind
rna
secondari
structur
nontransl
region
togeth
proteas
respons
cleavag
posttransl
modif
viral
polyprotein
flaviviru
protein
compos
er
membraneassoci
replic
complex
denv
shown
interact
dissoci
singlestrand
rna
modul
rna
synthesi
zikv
cooper
suppress
host
aktmammalian
target
rapamycin
mtor
pathway
inhibit
neurogenesi
induc
autophagi
reason
import
target
inhibit
could
impair
viral
propag
unfortun
crystal
structur
zikv
avail
th
june
contain
methyltransferas
domain
methyl
rna
cap
structur
rnadepend
rna
polymeras
domain
synthes
viral
rna
thu
essenti
zikv
surviv
establish
infect
host
cell
innat
immun
respons
initi
line
host
defens
type
interferon
ifn
product
signal
central
role
regard
protein
shown
inhibit
ifn
signal
evad
host
antivir
defens
protein
use
differ
mechan
depend
specif
flaviviru
target
signal
pathway
tickborn
enceph
viru
tbev
west
nile
viru
wnv
protein
inhibit
signal
transduc
activ
transcript
phosphoryl
nuclear
transloc
action
relat
ribbonrepresent
zikv
protein
structur
proteas
highlight
substrateligandbind
pocket
occupi
boron
inhibitor
compound
b
helicas
highlight
rna
atp
bind
site
predict
bind
pocket
enclos
hydrophob
caviti
around
flexibl
linker
join
di
diii
f
capsid
protein
predict
ligandbind
pocket
structur
avail
pdb
figur
built
use
vmd
program
http
wwwksuiuceduresearchvmd
polymeras
domain
japanes
enceph
viru
jev
block
tyrosin
phosphoryl
tyrosin
protein
kinas
yellow
fever
viru
yfv
bind
ifn
treatment
prevent
bind
ifnstimul
respons
promot
element
present
ifn
target
gene
recent
studi
show
zikv
express
result
proteasom
degrad
ifnregul
transcript
activ
human
mice
resembl
denv
mode
action
particularli
zikv
dock
studi
carri
predict
proteinprotein
interact
seven
absentia
homolog
protein
protein
studi
suggest
recruit
ubiquitinationdepend
degrad
ii
amino
acid
residu
involv
interact
andor
found
conserv
across
relat
flavivirus
anoth
structur
studi
zikv
indic
smallmolecul
inhibitorbind
site
structur
conserv
zikv
indic
potenti
mechan
function
inhibit
zikv
principl
small
molecul
interf
function
zikv
viral
protein
potenti
restrict
viru
replic
prevent
progress
zikvinfectionrel
pathogenesi
diseas
summar
sever
inhibitor
target
viral
protein
identifi
highthroughput
cellbas
screen
silico
dock
compound
librari
screen
even
undergon
vivo
test
polyphenol
present
green
tea
epigallocatechingal
egcg
shown
antivir
activ
mani
virus
hiv
herp
simplex
viru
hsv
influenza
viru
hepat
c
viru
hcv
recent
carneiro
cowork
vitro
assay
vero
cell
show
egcg
also
inhibit
entri
zikv
host
cell
least
log
higher
concentr
mm
author
propos
inhibit
probabl
relat
direct
interact
egcg
lipid
envelop
lead
subsequ
destruct
viru
particl
convers
egcg
contain
catechol
group
wellknown
pain
substructur
panassay
interfer
compound
promiscu
nonspecif
inhibit
mani
differ
target
subsequ
comput
studi
sharma
cowork
use
inducedfit
dock
molecular
dynam
md
druglik
properti
calcul
reveal
egcg
bind
hydrophob
site
locat
di
diii
close
flexibl
linker
fig
use
md
simul
show
egcg
block
major
conform
chang
membran
fusion
process
anoth
natur
product
nanchangmycin
streptomyc
nanchangensi
prove
potent
inhibitor
zikv
ht
assay
use
human
cell
ic
mm
fig
determin
whether
nanchangmycin
block
preor
postentri
step
viral
lifecycl
author
treat
cell
drug
remov
drug
h
postinfect
hpi
monitor
level
infect
h
later
nanchangmycin
inhibit
infect
suggest
block
earli
step
viral
lifecycl
unfortun
nanchangmycin
contain
reactiv
michael
acceptor
also
wellknown
pain
substructur
fernando
cowork
homolog
model
dock
md
simul
approach
predict
two
compound
could
inhibit
zikv
e
protein
two
small
molecul
preferenti
bind
glycanbind
domain
relat
virul
viru
antivir
activ
confirm
cell
cultur
assay
vero
cell
although
capsid
protein
emerg
promis
target
antiflavivir
agent
capsid
inhibitor
identifi
date
compound
shown
interact
capsid
protein
identifi
potent
inhibitor
four
serotyp
denv
vitro
vivo
reduc
viremia
viral
load
vital
organ
character
modeofact
show
directli
target
capsid
protein
present
bimod
antivir
activ
affect
assembl
andor
releas
entri
infecti
denv
particl
anoth
exampl
flavivir
capsid
inhibitor
biotinyl
deriv
compound
inhibit
hcv
infect
block
core
dimer
ic
mm
studi
support
hypothesi
inhibitor
viral
capsid
format
might
constitut
new
class
antivir
agent
therefor
could
also
applic
zikv
natur
product
like
polyphenol
known
antivir
activ
influenza
viru
coronaviru
cov
denv
other
way
mani
natur
product
test
proteas
abl
inhibit
zikv
proteas
activ
one
studi
compound
test
rel
high
concentr
mm
seven
compound
abl
inhibit
proteas
activ
ic
compound
determin
rang
mm
anoth
studi
five
flavonoid
one
natur
phenol
test
flavonoid
myricetin
ic
mm
quercetin
ic
mm
luteolin
ic
mm
isorhamnetin
ic
mm
apigenin
ic
mm
natur
phenol
curcumin
ic
mm
polyphenol
inhibit
enzym
noncompetit
mode
mean
could
perhap
alloster
inhibitor
dock
studi
show
compound
predict
bind
pocket
back
activ
site
zikv
howev
curcumin
quercetin
flavonoid
shown
promiscu
inhibitor
exampl
via
colloid
aggreg
curcumin
also
contain
reactiv
michael
acceptor
quercetin
catechol
wellknown
pain
substructur
might
make
compound
less
favor
ht
assay
develop
test
compound
inhibit
interact
ntermin
fragment
librari
fdaapprov
drug
investig
drug
drug
screen
use
assay
compound
produc
ic
mm
consid
pain
remain
compound
test
proteas
inhibit
activ
three
could
inhibit
ic
valu
rang
mm
three
compound
test
zikv
denv
wnv
jev
yfv
present
inhibitori
activ
close
nanomolar
level
wherea
temoporfin
fig
display
ec
halfmaxim
effect
concentr
flavivirus
test
low
nanomolar
concentr
therapeut
indic
three
compound
high
cc
concentr
inhibit
mammalian
cell
prolifer
consider
higher
ec
compound
also
abl
inhibit
zikv
replic
placent
epitheli
neuron
cell
inhibit
viral
polyprotein
cleavag
temoporfin
test
viremia
mous
model
lethal
mous
model
abl
inhibit
viremia
protect
chemic
structur
select
zika
viru
zikv
protein
inhibitor
envelop
glycoprotein
inhibitor
nanchangmycin
ic
mm
b
proteas
inhibitor
temoporfin
ic
mm
ic
mm
c
helicas
inhibitor
suramin
ec
mm
test
cellbas
assay
zikv
polymeras
inhibitor
sofosbuvir
ic
mm
ic
mm
ic
mm
e
methyltransferas
inhibitor
sinefungin
ic
mm
mice
mice
surviv
present
sign
neurolog
disord
similar
studi
done
use
structurebas
virtual
screen
vs
compound
drugbank
databas
top
candid
identifi
eight
clinic
approv
compound
belong
differ
drug
class
select
valid
studi
eight
select
compound
five
valid
proteas
inhibitor
compound
novobiocin
lopinavir
ritonavir
rifampicin
favor
safeti
profil
could
administr
pregnant
women
select
phenotyp
screen
two
compound
abl
inhibit
zikv
replic
compound
novobiocin
higher
select
index
test
vivo
dexamethason
immunosuppress
mice
dissemin
zikv
infect
novobiocin
treatment
significantli
higher
surviv
rate
lower
mean
blood
tissu
viral
load
well
less
sever
histopatholog
chang
untreat
control
similar
strategi
appropri
flaviviru
activ
compound
inhibit
zikv
close
relat
term
sequenc
structur
protein
base
upon
literatur
review
drug
select
test
zikv
could
match
follow
criteria
known
toxic
profil
human
pregnanc
ii
known
broadspectrum
antivir
activ
iii
known
antivir
activ
flaviviru
anoth
rna
viru
iv
coverag
broad
rang
indic
drug
class
bromocriptin
present
inhibitori
activ
cytopathiceffect
inhibit
assay
virusyieldreduct
assay
plaqueyieldreduct
assay
drug
predict
bind
proteas
molecular
dock
studi
also
present
inhibit
proteolyt
activ
enzym
twentyseven
hcv
proteas
inhibitor
test
zikv
ten
present
ic
valu
mm
best
two
inhibitor
test
determin
inhibit
type
present
competit
inhibit
profil
mean
might
bind
activ
site
aprotinin
amino
acid
bovin
trypsin
inhibitor
previous
test
wnv
proteas
also
inhibit
zikv
proteas
ic
nm
molecular
model
studi
predict
inhibitor
probabl
block
interact
contrast
analysi
crystal
structur
wnv
proteas
bovin
pancreat
trypsin
inhibitor
pdb
id
denv
proteas
bound
aprotinin
pdb
id
type
inhibitor
bind
occlud
substrat
site
focus
librari
proteas
inhibitor
bind
wnv
exosit
test
structur
similar
compound
screen
best
inhibitor
ic
mm
fig
ic
mm
ic
mm
also
test
furin
human
serin
proteas
cleavag
sequenc
prefer
similar
flavivir
proteas
show
effect
mm
compound
decreas
viral
yield
neuron
precursor
cell
best
inhibitor
test
use
vivo
mous
model
decreas
viremia
tenfold
unfortun
unfavor
pharmacokinet
profil
brecher
et
al
develop
assay
analyz
conform
chang
denv
proteas
use
luciferas
perform
vs
assay
use
alloster
site
conform
present
enzym
inact
state
twentynin
compound
select
vs
pipelin
test
proteas
inhibit
trial
three
subsequ
select
test
alloster
assay
abl
inhibit
proteas
compound
also
inhibit
viral
replic
denv
zikv
wnv
yfv
crystal
structur
elucid
md
studi
undertaken
understand
interact
conform
chang
protein
bound
inhibitor
inhibitor
complex
seen
crystal
structur
could
provid
model
assembl
form
site
polyprotein
process
guid
futur
drug
discoveri
process
zikv
proteas
helicas
display
atpas
rna
triphosphatas
rtpase
activ
studi
regard
inhibitor
mainli
use
vs
experiment
valid
although
recent
promis
preliminari
result
virtual
screen
zikv
develop
drug
target
zikv
could
involv
signific
hurdl
instanc
access
pocket
within
activ
site
complex
rel
shallow
previou
effort
discov
specif
inhibitor
denv
challeng
potenti
strategi
deal
issu
could
involv
target
site
zikv
put
alloster
site
discov
md
simul
current
perform
new
vs
snapshot
zikv
gener
md
test
strategi
challeng
relat
develop
potent
inhibitor
result
lack
specif
amino
acid
interact
atp
nucleobas
ribos
ring
ii
discoveri
specif
inhibitor
host
helicas
within
superfamili
atpas
activ
analysi
helicas
atpas
inhibitor
resveratrol
quercetin
test
mm
inhibitori
effect
atpas
activ
inhibit
respect
suramin
fig
antiparasit
drug
previous
character
denv
helicas
inhibitor
noncompetit
mode
action
recent
shown
inhibit
zikv
replic
ec
valu
mm
albulescu
cowork
suggest
experiment
assay
suramin
affect
zikv
bind
andor
entri
virion
biogenesi
attach
host
cell
author
also
suggest
suramin
might
inhibit
activ
might
affect
packag
bind
posit
charg
residu
capsid
protein
md
simul
perform
studi
protein
flexibl
conform
prefer
work
show
rna
bind
loop
influenc
presenc
rna
strand
stabl
close
conform
rna
bound
protein
differ
conform
observ
md
show
distinct
region
beneath
behind
atp
site
could
perhap
alloster
site
could
help
guid
discoveri
design
new
inhibitor
conform
strategi
guid
new
vs
experi
openzika
project
perform
ibm
world
commun
grid
wcg
openzika
virtual
screen
million
compound
zikv
protein
structur
target
relat
flavivirus
use
molecular
dock
wcg
qsar
model
filter
perform
inhous
project
ongo
sever
compound
current
assay
identifi
virtual
screen
flavivir
helicas
inhibitor
ivermectin
benzoxazol
activ
yfv
denv
respect
ivermectin
also
report
inhibit
denv
interact
nuclear
transport
importin
imp
ab
vitro
agent
also
interest
compound
test
zikv
protein
known
transmembran
domain
place
er
biolog
function
protein
fulli
establish
part
replic
complex
rc
studi
demonstr
induc
format
membran
web
form
scaffold
format
rc
also
interact
viral
protein
reason
good
target
develop
inhibitor
unfortun
search
inhibitor
face
mani
challeng
poor
pharmaceut
properti
inhibitor
difficulti
find
panflavivir
inhibitor
also
high
risk
develop
resist
virus
studi
regard
zikv
protein
inhibit
thu
far
aminothiazol
deriv
identifi
specif
denv
inhibitor
capabl
inhibit
four
serotyp
close
relat
flavivirus
identifi
ht
million
compound
use
denv
replicon
contain
luciferas
gene
face
problem
pharmacokinet
vivo
studi
high
lipophil
medicin
chemistri
attempt
overcom
issu
result
loss
antivir
select
denv
anoth
screen
use
nih
clinic
collect
naltrindol
analog
found
inhibit
denv
specif
point
mutat
confer
resist
compound
indic
probabl
target
protein
spiropyrazolopyridon
compound
found
inhibit
denv
serotyp
fact
correl
low
ident
flavivirus
even
differ
serotyp
denv
compound
abl
suppress
viremia
mous
model
denv
serotyp
infect
two
compound
hit
screen
yfv
mutat
residu
confer
resist
yfv
compound
differ
type
denv
methyltransferas
mtase
inhibitor
also
test
zikv
mtase
class
inhibitor
test
sadenosyllmethionin
sam
analog
rna
cap
analog
compound
target
alloster
site
denv
mtase
sadenosyllhomocystein
sah
sam
analog
sinefungin
structur
zikv
mtase
sam
analog
sinefungin
recent
elucid
construct
inhibitor
connect
sinefungin
cap
analog
attach
linker
propos
could
perhap
grant
higher
affin
protein
vs
use
hydrophob
site
close
sam
pocket
perform
compound
ten
compound
best
score
select
experiment
screen
four
abl
inhibit
viral
growth
concentr
mm
best
inhibitor
present
ic
valu
mm
jain
cowork
develop
sam
analog
encroach
guanosin
triphosph
gtp
cap
pocket
zikv
mtase
start
crystallograph
structur
bound
sam
develop
analog
attach
group
gave
compound
capac
bind
part
rna
tunnel
occupi
cap
methyl
site
design
zikvspecif
mtase
inhibitor
challeng
case
denv
flavirus
mainli
owe
select
compound
sambind
samutil
protein
present
host
cell
similar
human
rna
dna
mtase
moreov
anoth
issu
design
competit
mtase
inhibitor
high
cellular
sam
concentr
still
issu
overcom
field
kinas
indic
could
also
feasibl
mtase
rdrp
remain
one
promis
target
demonstr
larg
number
market
nucleosid
inhibitor
ni
nonnucleosid
inhibitor
nni
drug
avail
treatment
cytomegaloviru
hepat
b
c
virus
nucleosid
analog
prodrug
sofosbuvir
use
part
certain
combin
therapi
treat
hcv
ni
like
cand
omethylsubstitut
nucleosid
cmethylsubstitut
nucleosid
omethylsubstitut
nucleosid
deoxynucleosid
deriv
cazido
substitut
heterobasemodifi
nucleosid
neplanocin
test
zikv
promis
inhibitor
nucleosid
ic
valu
mm
similar
observ
found
ribonucleosid
triphosph
analog
test
polymeras
cmethyland
cethinylsubstitut
ribonucleosid
triphosph
best
inhibitor
compound
test
abil
incorpor
rna
chain
termin
elong
analog
show
abil
ic
mm
cmeutp
ic
mm
cethynylutp
ic
mm
fig
atp
analog
test
polymeras
anoth
studi
compound
led
strongest
enzym
inhibit
cmethyl
atp
best
inhibitor
present
ic
valu
mm
mm
adenosin
analog
call
inhibit
zikv
cell
cultur
well
mous
model
compound
alreadi
present
broadspectrum
activ
wide
rang
rna
virus
west
nile
tickborn
yellow
fever
marburg
ebola
previou
studi
suggest
act
polymeras
promot
chain
termin
viral
rna
synthesi
recent
studi
anoth
adenosin
analog
known
flavivir
polymeras
inhibitor
test
cellbas
assay
zikv
compound
cmethyladenosin
inhibit
zikv
prolifer
vero
cell
anim
model
decreas
viremia
delay
morbid
mortal
caus
zikv
although
author
test
compound
zikv
protein
repres
promis
candid
drug
discoveri
today
volum
number
novemb
nucleosid
inhibitor
polymeras
made
great
progress
howev
major
challeng
nibas
antivir
approach
includ
toxic
ad
complic
prodrug
requir
host
kinas
convert
triphosph
form
ni
use
drug
repurpos
strategi
xu
et
al
test
compound
alreadi
use
hcv
polymeras
sofosbuvir
fig
ni
fig
nni
compound
inhibit
zikv
polymeras
ic
valu
mm
mm
respect
mutat
confer
resist
nucleosid
analog
inhibitor
hcv
also
led
resist
sofosbuvir
zikv
case
mumtaz
cowork
test
sofosbuvir
zikv
use
vero
cell
measur
level
activ
sofosbuvir
metabolit
mass
spectrometri
sofosbuvir
show
celltypedepend
activ
inhibit
zikv
ic
mm
cell
correl
differ
intracellular
concentr
activ
metabolit
sofosbuvir
higher
cell
compar
cell
result
highlight
import
care
select
cell
system
repurpos
trial
prodrug
evalu
antivir
activ
pharmacophorebas
strategi
use
search
inhibitor
research
construct
model
polymeras
methyltransferas
use
molecul
ribavirin
use
model
conduct
vs
zinc
databas
found
candid
polymeras
candid
methyltransferas
candid
dock
respect
target
three
potenti
lead
select
protein
base
dock
score
compound
best
dock
score
polymeras
mtase
result
remain
confirm
valid
assay
lim
et
al
perform
fragmentbas
screen
xray
crystallographi
target
denv
polymeras
elucid
alloster
bind
pocket
base
thumb
subdomain
close
enzym
activ
site
promis
alloster
inhibitor
develop
structureguid
design
activ
denv
polymeras
biochem
cellbas
assay
inhibit
enzym
ic
valu
mm
strategi
could
probabl
use
zikv
alloster
inhibitor
design
viral
protein
conserv
sequenc
similar
structur
zikv
well
flavivirida
member
small
genom
requir
host
cell
machineri
carri
sever
core
function
essenti
viral
replic
addit
inhibit
function
viral
protein
attract
broadspectrum
strategi
target
host
cell
process
often
employ
multipl
virus
less
prone
develop
drug
resist
recent
describ
inhibitor
commonli
target
cellular
function
zikv
found
tabl
see
supplementari
materi
onlin
review
moreov
also
present
special
section
regard
antivir
effect
type
ii
interferon
supplementari
materi
virus
reli
suppli
nucleosid
host
cell
maintain
proper
rna
replic
furthermor
evid
inhibit
nucleosid
biosynthesi
trigger
activ
antivir
interferonstimul
gene
human
cell
thu
host
enzym
involv
de
novo
biosynthesi
nucleosid
inosin
monophosph
dehydrogenas
impdh
dihydroorot
dehydrogenas
dhodh
interest
target
broadspectrum
antivir
therapi
impdh
catalyz
oxid
convers
inosin
monophosph
xanthosin
first
commit
ratelimit
step
guanin
nucleotid
biosynthet
pathway
known
inhibitor
impdh
includ
ribavirin
eicar
mycophenol
acid
mpa
ribavirin
one
first
clinic
use
broadspectrum
antivir
commonli
employ
combin
therapi
treat
hcv
thought
multipl
mechan
action
includ
inhibit
viral
polymeras
host
impdh
found
inhibit
virusinduc
cytopath
effect
cpe
sever
flavivirus
includ
zikv
ec
mgml
recent
studi
test
activ
known
broadspectrum
antivir
includ
ribavirin
yield
poor
inhibit
virusinduc
cpe
ec
mm
strain
conclud
suitabl
candid
zikv
therapeut
nucleosid
biosynthesi
inhibitor
also
test
studi
among
mpa
ec
mm
brequinar
ec
mm
ec
mm
latter
two
compound
inhibit
dihidroorot
dehydrogenas
dhodh
orotidyl
acid
omp
decarboxylas
respect
two
enzym
involv
pyrimidin
biosynthesi
import
highlight
sever
nucleotid
biosynthesi
inhibitor
suppress
viral
growth
innat
immun
studi
lucashourani
cowork
author
show
pyrimidin
depriv
use
brequinar
anoth
compound
directli
respons
antivir
activ
pyrimidin
biosynthesi
inhibitor
rather
involv
induct
metabol
stress
subsequ
trigger
cellular
immun
respons
barrow
cowork
also
test
mpa
present
potent
antizikv
activ
inhibit
zikv
infect
hela
hnsc
haec
cell
screen
also
detect
nucleosid
biosynthesi
inhibitor
azathiopurin
mercaptopurin
hydrat
mycophenol
mofetil
prodrug
mpa
thioguanin
anoth
cellbas
screen
carri
pascoalino
et
al
identifi
ec
ae
mm
anoth
pyrimidin
biosynthesi
inhibitor
ec
ae
mm
inhibit
thymidyl
synthas
enzym
catalyz
final
step
thymidin
biosynthesi
floxuridin
also
show
dosedepend
inhibit
zikv
replic
studi
tiwari
et
al
although
pregnanc
categori
label
system
replac
worth
note
compound
gener
classifi
pregnanc
categori
fda
thu
present
posit
evid
human
fetal
risk
unexpect
deplet
cellular
pool
nucleotid
certainli
affect
proper
develop
fetu
flavivir
infect
associ
alter
lipid
homeostasi
membran
structur
infect
cell
denv
infect
exampl
known
induc
dramat
reloc
fatti
acid
synthas
fa
site
viral
replic
cholesterol
identifi
import
modul
host
respons
sever
flavivirus
exact
mechan
modul
occur
yet
fulli
understood
nevertheless
inhibit
cholesterol
biosynthesi
pathway
repres
attract
therapeut
approach
sever
enzym
involv
cholesterol
biosynthesi
mevalon
decarboxylas
hmgcoa
synthas
squalen
synthetas
found
import
effici
replic
denv
cell
line
lovastatin
hmgcoa
reductas
inhibitor
test
zikv
part
cellbas
screen
fdaapprov
drug
activ
confirm
doserespons
assay
ec
ae
mm
antiflavivir
activ
previous
report
hcv
denv
moreov
sarkey
cowork
demonstr
lovastatin
attenu
nervou
system
injuri
anim
model
could
use
inflammatori
peripher
nerv
diseas
includ
syndrom
consequ
zikv
infect
nevertheless
although
consid
safe
treatment
lovastatin
show
evid
benefici
impact
dengu
infect
random
doubleblind
placebocontrol
trial
mevastatin
also
antizikv
activ
concentr
mm
doserespons
concentr
mm
mevastatin
known
induc
apoptosi
could
perhap
explain
lack
antivir
efficaci
higher
concentr
nordihydroguaiaret
acid
ndga
deriv
tetraomethyl
nordihydroguaiaret
acid
n
test
zikv
show
inhibit
low
micromolar
rang
ic
valu
mm
respect
polyphenol
whose
mechan
action
fulli
elucid
could
involv
promiscu
inhibit
see
aforement
section
pain
proteas
section
ndga
shown
affect
hcv
replic
reduct
amount
lipid
droplet
thought
mediat
sterol
regulatori
elementbind
protein
srebp
pathway
earli
studi
establish
ndga
inhibitor
shown
bind
sever
molecular
partner
glucos
transport
tyrosin
kinas
even
transthyretin
molecular
mechan
clinic
applic
compound
thoroughli
review
cowork
protein
kinas
catalyz
addit
phosphat
group
sever
molecular
entiti
protein
lipid
carbohydr
thu
control
mani
cellular
process
viral
replic
requir
hijack
sever
cellular
mechan
expect
hinder
modul
kinas
activ
inde
host
cell
kinas
implic
replic
sever
rna
viru
famili
tang
cowork
carri
transcriptom
analysi
human
neural
progenitor
cell
hnpc
enrich
analysi
supplementari
data
indic
sever
upregul
gene
relat
protein
kinas
activ
xu
et
al
perform
twostep
drug
repurpos
screen
initi
measur
activ
subsequ
measur
cell
viabil
primari
hit
use
approach
abl
detect
investig
cyclindepend
kinas
inhibitor
cdki
inhibit
zikv
infect
ec
valu
mm
test
addit
cdki
identifi
nine
could
inhibit
zikv
replic
among
seliciclib
purin
analog
also
call
roscovitin
inhibit
zikv
infect
submicromolar
concentr
author
conclud
result
suggest
one
host
cdk
might
import
zikv
replic
flavivirus
known
encod
cdk
axl
greek
word
anexelekto
uncontrol
tyrosin
kinas
receptor
tkr
thought
mediat
viral
attach
host
cell
function
also
respons
downregul
interferon
product
although
recognit
might
unrel
kinas
activ
axl
inhibitor
found
inhibit
zikv
infect
rate
rausch
et
al
screen
librari
compound
human
osteosarcoma
cell
found
zikv
inhibitor
eight
protein
kinas
target
includ
five
tkr
among
two
axl
inhibitor
axl
inhibitor
exhibit
activ
differ
cell
line
hbmec
indic
effect
celltyp
specif
author
also
point
cell
highli
permiss
zikv
infect
despit
show
detect
axl
express
level
suggest
receptor
essenti
infect
hypothesi
corrobor
vivo
studi
intracellular
membran
traffic
mechan
also
exploit
virus
depend
heavili
enzymat
activ
protein
kinas
regul
vesicl
traffic
via
phosphoryl
specif
subunit
associ
adaptor
protein
ap
bekerman
cowork
test
antivir
activ
erlotinib
sunitinib
sever
differ
flavivirus
genera
includ
zikv
ec
valu
mm
respect
present
sever
line
evid
indic
like
target
kinas
gassoci
kinas
gak
possibl
candid
axl
kit
protooncogen
receptor
tyrosin
kinas
kit
protooncogen
ret
monel
et
al
describ
indepth
vacuol
zikvinfect
cell
suggest
undergo
paraptosislik
death
associ
activ
phophoinositid
membraneassoci
protein
kinas
mapk
therefor
test
activ
sever
kinas
inhibitor
verifi
could
prevent
onset
vacuol
particularli
specif
akt
triciribin
inhibitor
howev
none
test
inhibitor
block
zikv
infect
viral
replic
extens
hijack
er
function
er
intim
associ
intracellular
membran
network
remodel
framework
viral
polyprotein
express
process
event
gener
consider
amount
stress
organel
correct
express
process
nascent
protein
paramount
effici
viral
replic
sever
host
drug
discoveri
today
volum
number
novemb
protein
respons
monitor
proper
protein
synthesi
fold
degrad
impair
function
result
reduc
viral
assembl
bud
exampl
er
membran
complex
emc
aglucosidas
cyclophilin
proteasom
element
inhibitor
investig
context
emc
ensembl
nine
compon
thought
assist
protein
fold
shown
upregul
zikvinfect
cell
sever
protein
complex
multipass
membran
protein
anoth
key
player
relat
protein
metabol
aglucosidas
erresid
enzym
catalyz
remov
glucos
unit
nlink
oligosaccharid
process
crucial
nascent
glycoprotein
matur
subsequ
correct
fold
glycoprotein
fail
process
subject
abnorm
accumul
er
erassoci
degrad
erad
nascent
misfold
protein
retrotransloc
back
cytosol
ubiquitin
degrad
proteasom
aglucosidas
inhibitor
exhibit
broad
antivir
activ
multipl
genera
celgosvir
castanospermin
show
poor
activ
zikv
cpebas
assay
vero
cell
infect
either
strain
ec
mm
case
xin
cowork
carri
quantit
proteom
analysi
cell
infect
zikv
found
upregul
gene
two
proteinrel
pathway
ubiquitinproteasom
system
up
unfold
protein
respons
upr
subsequ
test
dosedepend
effect
bortezomib
ec
nm
ec
mm
two
proteasom
inhibitor
zikvinfect
vero
cell
also
found
bortezomib
reduc
viral
load
sign
patholog
zikvinfect
mice
bortezomib
also
detect
one
previou
screen
show
moder
toxic
hnsc
cell
line
expect
base
mechan
primari
use
anticanc
agent
cyclophilin
cytoplasm
protein
respons
isomer
prolin
peptid
bond
tran
ci
conform
thu
facilit
protein
fold
activ
shown
essenti
hiv
hcv
replic
cyclosporin
target
cyclophilin
found
inhibit
hcv
wnv
denv
yfv
infect
barrow
et
al
detect
cyclosporin
potenti
hit
display
controversi
result
even
enhanc
infect
mm
compar
control
flavivirus
includ
zikv
endocytos
clathrinmedi
mechan
undergo
phdepend
fusion
process
endosom
membran
fuse
viral
envelop
action
envelop
protein
step
occur
e
protein
must
undergo
conform
chang
expos
fusion
loop
li
cowork
identifi
probabl
capabl
block
viral
entri
modifi
hostcel
membran
properti
calcul
ec
nm
compound
also
abl
reduc
viremia
mice
nonhuman
primat
ii
protect
mous
embryo
microcephali
antimalari
drug
chloroquin
known
exhibit
broadspectrum
antivir
activ
weak
base
pk
pk
ph
lysosom
presenc
chloroquin
increas
increas
thought
respons
inhibit
phdepend
fusion
step
viral
entri
chloroquin
test
zikv
show
activ
vero
cell
ae
mm
human
brain
microvascular
endotheli
cell
ae
mm
human
neural
stem
cell
ae
mm
reduc
number
infect
cell
vitro
inhibit
viru
product
cell
death
promot
zikv
infect
display
rel
minor
cytotox
effect
cc
rang
mm
moreov
chloroquin
partial
revers
morpholog
chang
induc
zikv
mous
neurospher
chloroquin
found
reduc
viral
burden
placenta
zikvinfect
pregnant
mice
howev
also
show
controversi
result
anoth
studi
quinacrin
ec
ae
mm
mefloquin
ec
ae
mm
ec
ae
mm
antimalari
drug
similar
mechan
action
also
recent
test
zikv
anticanc
drug
obatoclax
promot
rapid
neutral
lysosom
ph
show
activ
yfv
ec
mm
wnv
ec
ae
mm
zikv
ec
ae
mm
author
suggest
anticanc
antivir
activ
independ
reli
differ
mechan
obatoclax
also
test
retin
pigment
epitheli
rpe
cell
display
ec
valu
ae
mm
recoveri
infectedcel
viabil
addit
also
detect
drug
screen
cell
ec
valu
mm
saliphenylhalamid
saliph
anoth
known
viral
entri
blocker
act
inhibit
vacuolar
atpas
test
vero
cell
yield
ec
valu
mm
strain
mm
strain
also
test
kuivanen
et
al
rpe
cell
yield
ec
valu
ae
mm
niclosamid
block
acidif
endosom
albeit
use
differ
mechan
yet
fulli
elucid
detect
screen
zikv
cell
show
ec
valu
mm
base
measur
intracellular
viral
rna
niclosamid
fdaapprov
drug
formerli
design
pregnanc
categori
b
broadli
use
treatment
intestin
helminthiasi
drug
pregnanc
categori
b
undergon
control
studi
pregnant
women
fail
demonstr
risk
fetu
anim
reproduct
studi
inhibitor
endosom
sort
complex
requir
transport
escrt
machineri
could
promis
target
zikv
drug
discoveri
see
supplementari
materi
onlin
moreov
zikv
inhibitor
unclassifi
unconfirm
mechan
action
also
discuss
see
supplementari
materi
onlin
one
key
step
drug
discoveri
pipelin
develop
screen
assay
assess
antivir
activ
compound
virus
depend
cell
machineri
replic
reason
vitro
assay
develop
use
host
cell
cultur
viral
replic
zikv
recent
shown
infect
differ
cell
multipl
speci
find
show
divers
cell
line
use
studi
zikv
infect
provid
good
framework
drug
discoveri
process
also
present
discuss
avail
screen
assay
antizikv
hit
discoveri
see
supplementari
materi
onlin
although
scientif
commun
devot
consider
effort
search
vaccin
antivir
drug
prevent
treat
zikv
infect
still
approv
treatment
flaviviru
vaccin
prevent
rel
short
time
gone
structur
protein
viru
wealth
data
owe
current
state
known
antizikv
compound
probabl
way
go
clinic
trial
discov
candid
undertaken
especi
consid
patient
includ
immunosuppress
pregnant
women
underli
medic
condit
regard
one
strategi
overcom
risk
teratogenesi
develop
new
drug
treat
zika
base
twostag
phase
ii
clinic
trial
firststag
focus
test
efficaci
nonpregn
patient
secondstag
focus
pregnant
women
possibl
reduc
overal
cost
trial
facilit
logist
set
enhanc
safeti
level
patient
mani
compound
clearli
unsuit
patient
moreov
one
frequent
issu
see
mani
publish
screen
use
unrealist
concentr
eg
mm
compound
eg
cytotox
anticanc
compound
could
never
use
pregnant
women
much
work
describ
herein
would
benefit
experienc
medicin
chemist
involv
advis
util
compound
select
would
also
help
avoid
compound
like
pain
report
hit
sever
screen
ultim
recent
advanc
discoveri
antizikv
agent
zikv
protein
structur
host
target
protein
structur
understand
diseas
crucial
advanc
fight
zikv
also
use
next
emerg
viru
outbreak
respond
also
heed
lesson
learn
zikv
drug
discoveri
success
avoid
deadend
futur
author
except
se
ceo
collabor
pharmaceut
conflict
interest
declar
view
reflect
author
